Overview

* Tarsus Q2 revenue rises 152% yr/yr to $102.7 mln, beating analyst expectations

* Net loss for Q2 narrows to $20.3 mln from $33.3 mln last year

* Co's DTC campaign boosts XDEMVY prescriptions and prescriber base significantly

Outlook

* Tarsus expects peak potential of XDEMVY to exceed initial expectations

* Company plans Phase 2 study for TP-04 in H2 2025

* Tarsus to initiate Phase 2 study for TP-05 in 2026

* Company anticipates European approval for XDEMVY in 2027

Result Drivers

* XDEMVY SALES - Record net product sales of $102.7 mln, up 152% yr/yr, driven by strong demand and prescriber growth

* DTC CAMPAIGN - Direct-to-consumer advertising significantly increased prescriptions and prescriber base

* PRESCRIBER EXPANSION - Over 20,000 Eye Care Professionals now prescribing XDEMVY, exceeding initial targets

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $102.66 $95.70

Revenue mln mln (6

Analysts

)

Q2 EPS -$0.48

Q2 Net -$20.34

Income mln

Q2 Basic -$0.48

EPS

Q2 $124.84

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc ( TARS ) is $72.00, about 42.8% above its August 5 closing price of $41.15

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)